Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR5 | Q9H228 | 9/20 | 0.56 |
| ▸ | S1PR1 | P21453 | 5/20 | 0.56 |
| ▸ | FUCA1 | P04066 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | LTA4H | P09960 | 1/20 | 0.50 |
| ▸ | RORC | P51449 | 1/20 | 0.48 |
| ▸ | ACHE | P22303 | 1/20 | 0.47 |
| ▸ | UBE2M | P61081 | 1/20 | 0.47 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.47 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23297889 | 1.00 | S1PR5 (0.56) | S1PR5S1PR1FUCA1ALDH1A1LTA4H | |
| SCHEMBL22435919 | 1.00 | S1PR5 (0.56) | S1PR5S1PR1FUCA1ALDH1A1LTA4H | |
| SCHEMBL25896427 | 1.00 | S1PR5 (0.56) | S1PR5S1PR1FUCA1ALDH1A1LTA4H | |
| SCHEMBL500367 | 1.00 | S1PR5 (0.56) | S1PR5S1PR1FUCA1ALDH1A1LTA4H | |
| SCHEMBL500364 | 1.00 | S1PR5 (0.56) | S1PR5S1PR1FUCA1ALDH1A1LTA4H | |
| Hydrochloric Acid SCHEMBL15567085 | 0.98 | S1PR5 (0.55) | S1PR5S1PR1FUCA1ALDH1A1LTA4H | |
| SCHEMBL15151079 | 0.89 | S1PR5 (0.51) | S1PR5S1PR1FUCA1LTA4HRORC | |
| SCHEMBL15567084 | 0.89 | S1PR5 (0.51) | S1PR5S1PR1FUCA1LTA4HRORC | |
| SCHEMBL4513757 | 0.89 | S1PR5 (0.51) | S1PR5S1PR1FUCA1RORCACHE | |
| SCHEMBL6231248 | 0.88 | S1PR5 (0.65) | S1PR5S1PR1FUCA1ALDH1A1RORC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023224894-A1 | MACROCYCLES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | MERCK SHARP & DOHME LLC (US) | 2023-11-23 | — | — | WO | disclosed |
| EP-4168002-A1 | METHODS FOR DELAYING, PREVENTING, AND TREATING ACQUIRED RESISTANCE TO RAS INHIBITORS | Revolution Medicines, Inc. (US) | 2023-04-26 | — | — | EP | disclosed |
| CN-108884068-B | 1-cyano-pyrrolidine derivatives as DUB inhibitors | 特殊治疗有限公司 | 2021-02-26 | — | — | CN | disclosed |
| US-9969742-B2 | Imidazotriazinone compounds | IRONWOOD PHARMACEUTICALS, INC. (US) | 2018-05-15 | — | — | US | disclosed |
| EP-3277677-A1 | 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS | Mission Therapeutics Limited (GB) | 2018-02-07 | — | — | EP | disclosed |
| US-9850249-B2 | PDE9 inhibitors with imidazo triazinone backbone | H. LUNDBECK A/S (DK) | 2017-12-26 | — | — | US | disclosed |
| US-9850249-B2 | PDE9 inhibitors with imidazo triazinone backbone | H. LUNDBECK A/S (DK) | 2017-12-26 | — | — | US | disclosed |
| EP-3178820-B1 | PDE9- INHIBITORS WITH IMIDAZO TRIAZINONE BACKBONE | H LUNDBECK AS (DK) | 2017-12-20 | — | — | EP | disclosed |
| US-20170327502-A1 | IMIDAZOTRIAZINONE COMPOUNDS | IRONWOOD PHARMACEUTICALS INC (US) | 2017-11-16 | — | — | US | disclosed |
| US-9725453-B2 | Imidazotriazinone compounds | IRONWOOD PHARMACEUTICALS, INC. (US) | 2017-08-08 | — | — | US | disclosed |
| WO-2008116881-A1 | SUBSTITUTED PYRROLIDINE AMIDES, THE PRODUCTION THEREOF, AND THE USE THEREOF AS MEDICATIONS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-10-02 | — | — | WO | disclosed |
| EP-1975165-A1 | Substituted pyrrolidinamides, their production and utilisation as medicine | Boehringer Ingelheim Pharma GmbH & Co. KG (DE) | 2008-10-01 | — | — | EP | disclosed |
| CN-101175724-A | Pyrrolidine derivative or salt thereof | ASTELLAS PHARMA INC (JP) | 2008-05-07 | — | — | CN | disclosed |
| EP-1882684-A1 | PYRROLIDINE DERIVATIVE OR SALT THEREOF | Astellas Pharma Inc. (JP) | 2008-01-30 | — | — | EP | disclosed |
| US-7153851-B2 | 10-(3-cyclopropylaminomethyl-1-pyrrolidinyl)pyridobenzoxazinecarboxylic acid derivative effective against resistant bacterium | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2006-12-26 | — | — | US | disclosed |
| WO-2006100036-A1 | 3, 4-SUBSTITUTED PYRROLIDINE DERIVATIVES FOR THE TREATMENT OF HYPERTENSION | NOVARTIS AG (CH) | 2006-09-28 | — | — | WO | disclosed |
| US-20060173225-A1 | Process for the production of para-diethylbenzene | INDIAN PETROCHEMICALS CORPORATION LIMITED | 2006-08-03 | — | — | US | disclosed |
| US-20050182052-A1 | 10-(3-cyclopropylaminomethyl-1-pyrrolidinyl)pyridobenzoxazinecarboxylic acid derivative effective against resistant bacterium | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2005-08-18 | — | — | US | disclosed |
| EP-1486500-A1 | 10-(3-CYCLOPROPYLAMINOMETHYL-1-PYRROLIDINYL)PYRIDOBENZOXAZINECARBOXYLIC ACID DERIVATIVE EFFECTIVE AGAINST RESISTANT BACTERIUM | Kyorin Pharmaceutical Co., Ltd. (JP) | 2004-12-15 | — | — | EP | disclosed |
| CN-1425008-A | 3-aminoquinazolin-2, 4-dione antibacterial agents | WARNER LAMBERT CO (US) | 2003-06-18 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170327502-A1 | IMIDAZOTRIAZINONE COMPOUNDS | PDE9A, PDE12, PDE4A | S1PR5 1335/4885S1PR1 1663/4885FUCA1 3870/4885 |
| US-20050182052-A1 | 10-(3-cyclopropylaminomethyl-1-pyrrolidinyl)pyridobenzoxazinecarboxylic acid derivative effective against resistant bacterium | RRP15, RRP12, RRS1 | S1PR5 2180/4885S1PR1 2298/4885FUCA1 3526/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.